VivoSensMedical GmbH (VSM) is showcasing a world first at CeBIT 2016 with its OvulaRing biosensor, one of the most cutting-edge and simple methods for menstrual cycle diagnostics and pinpointing peak fertility.
VivoSensMedical GmbH wants to improve diagnostics and set new standards in gynecological, reproductive and sexual medicine. The startup from Saxony is exhibiting the OvulaRing, its inaugural digital healthcare innovation, at CeBIT 2016 in Hannover. The OvulaRing is an intravaginal biosensor that identifies the fertile days in a woman’s cycle, which is useful for medical diagnostics of the menstrual cycle, in aiding conception or as a natural, hormone-free form of contraception. The OvulaRing was developed with the aid of an EXIST entrepreneurial grant from the German Federal Ministry of Economics and Technology.
"CeBIT is an excellent networking opportunity for us," says Bettina Brammer, a managing partner and head of marketing & sales at VivoSensMedical GmbH. "By exhibiting at the fair, we want to reach out to cooperation partners and decision-makers and flag up new opportunities in digital diagnostics for the growth markets of gynecology and reproductive medicine that help to personalize and therefore improve patient treatment." The OvulaRing is the first in-body wearable ovulation tracker, a patented and licensed medical device, and already in use by more than 1,000 women – making it a prime example of this kind of technology. The small device uses an app and mobile software based on medical algorithms to continuously analyze core body temperature measurements in order to track a woman’s complete menstrual cycle and simply and precisely identify her most fertile days – an absolute first. This places OvulaRing at the interface between patients and doctors when it comes to self-tracking and telemedical personalized treatment.
VivoSens Medical GmbH (04107 Leipzig, Germany), Hall 11, Stand C54, Topic: CeBIT SCALE 11, partner of futureSAX